- Home
- BRTX vs RNAZ Comparison
BRTX vs RNAZ Comparison
Compare BRTX & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRTX | RNAZ |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.6M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRTX | RNAZ |
|---|---|---|
| Price | $0.40 | $5.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 22.8M | 9.8K |
| Earning Date | 05-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $81,000.00 | N/A |
| Revenue This Year | $298.39 | N/A |
| Revenue Next Year | $64.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $5.01 |
| 52 Week High | $2.04 | $20.99 |
Technical Indicators
Market Signals| Indicator | BRTX | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 65.99 | 25.39 |
| Support Level | $0.20 | N/A |
| Resistance Level | $1.20 | $9.37 |
| Average True Range (ATR) | 0.07 | 0.61 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 44.86 | 17.49 |
Price Performance
Historical ComparisonAbout BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.